Alx Oncology Holdings 

Yahoo Finance • 15 days ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend... Full story

Yahoo Finance • 2 months ago

ALX Oncology initiated with a Buy at UBS

UBS initiated coverage of ALX Oncology (ALXO) with a Buy rating and $6 price target The company has a potential blockbuster program with a CD47 combo currently in Phase II for metastatic breast cancer, the analyst tells investors in a rese... Full story

Yahoo Finance • 2 months ago

ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing

Earnings Call Insights: ALX Oncology Holdings Inc. (ALXO) Q4 2025 MANAGEMENT VIEW * Jason Lettmann, CEO, introduced the appointment of Dr. Barbara Klencke as the permanent Chief Medical Officer, following her interim leadership since S... Full story

Yahoo Finance • 2 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets a... Full story

Yahoo Finance • 3 months ago

3 Promising Penny Stocks With Market Caps Over $100M

As February begins, major U.S. stock indexes have shown strong gains, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing a record high. In this context of market optimism, investors often seek out opportunities... Full story

Yahoo Finance • 3 months ago

Cheap high flyer healthcare stocks - high momentum and low valuation

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As earnings season ramps up and geopolitical tensions keep affecting the markets, below is a list of the top 10 heal... Full story

Yahoo Finance • 5 months ago

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 a... Full story

Yahoo Finance • 5 months ago

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment... Full story

Yahoo Finance • 5 months ago

ALX Oncology to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat... Full story

Yahoo Finance • 6 months ago

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast Cancer trial remains on trac... Full story

Yahoo Finance • 7 months ago

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX... Full story

Yahoo Finance • 7 months ago

Friday 9/19 Insider Buying Report: AROC, ALXO

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Archrock, a filing with the SEC revealed... Full story

Yahoo Finance • 8 months ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief M... Full story

Yahoo Finance • 8 months ago

ALX Oncology to Participate in Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat... Full story

Yahoo Finance • 8 months ago

Unusual volume stocks in Friday's session

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT EEIQ [https://www.chartmill.com/stock/quote/EEIQ/p... Full story

Yahoo Finance • 8 months ago

ALX Oncology doses first patient in phase 1 trial of EGFR cancer drug

SOUTH SAN FRANCISCO - ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotechnology company with a current market capitalization of $53 million, announced Tuesday that the first patient has been dosed in its Phase 1 clinical tri... Full story

Yahoo Finance • 8 months ago

Curious about the stocks that are showing activity after the closing bell on Monday?

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT LASE [https://www.chartmill.com/stock/q... Full story

Yahoo Finance • 8 months ago

What's going on in today's session

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT SNGX... Full story

Yahoo Finance • 9 months ago

Earnings call transcript: ALS Oncology Q2 2025 reports EPS miss

ALS Oncology Holdings (ALSN) reported its second-quarter 2025 earnings on August 12, revealing an earnings per share (EPS) of -0.49 USD, which fell short of the forecasted -0.43 USD. The company’s stock closed at 0.61 USD, with a slight de... Full story

Yahoo Finance • 9 months ago

ALX Oncology GAAP EPS of -$0.49 misses by $0.04

* ALX Oncology press release [https://seekingalpha.com/pr/20198601-alx-oncology-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:ALXO [https://seekingalpha.com/symbol/ALXO]): Q2 GAAP EPS of -$0.49 miss... Full story